Sigma-1 and dopamine D2/D3 receptor occupancy of pridopidine in healthy volunteers and patients with Huntington disease:
- PDF / 4,795,415 Bytes
- 13 Pages / 595.276 x 790.866 pts Page_size
- 5 Downloads / 180 Views
ORIGINAL ARTICLE
Sigma-1 and dopamine D2/D3 receptor occupancy of pridopidine in healthy volunteers and patients with Huntington disease: a [18F] fluspidine and [18F] fallypride PET study Igor D. Grachev 1,2 & Philipp M. Meyer 3 & Georg A. Becker 3 & Marcus Bronzel 4 & Doug Marsteller 5 & Gina Pastino 5 & Ole Voges 4 & Laura Rabinovich 5 & Helena Knebel 5 & Franziska Zientek 3 & Michael Rullmann 3 & Bernhard Sattler 3 & Marianne Patt 3 & Thilo Gerhards 3 & Maria Strauss 6 & Andreas Kluge 4 & Peter Brust 7 & Juha-Matti Savola 5 & Mark F. Gordon 5 & Michal Geva 8 & Swen Hesse 3 & Henryk Barthel 3 & Michael R. Hayden 8 & Osama Sabri 3 Received: 3 June 2020 / Accepted: 7 September 2020 # The Author(s) 2020
Abstract Purpose Pridopidine is an investigational drug for Huntington disease (HD). Pridopidine was originally thought to act as a dopamine stabilizer. However, pridopidine shows highest affinity to the sigma-1 receptor (S1R) and enhances neuroprotection via the S1R in preclinical studies. Using [18F] fluspidine and [18F] fallypride PET, the purpose of this study was to assess in vivo target engagement/receptor occupancy of pridopidine to the S1R and dopamine D2/ D3 receptor (D2/D3R) at clinical relevant doses in healthy volunteers (HVs) and as proof-of-concept in a small number of patients with HD. Methods Using [18F] fluspidine PET (300 MBq, 0–90 min), 11 male HVs (pridopidine 0.5 to 90 mg; six dose groups) and three male patients with HD (pridopidine 90 mg) were investigated twice, without and 2 h after single dose of pridopidine. Using [18F] fallypride PET (200 MBq, 0–210 min), four male HVs were studied without and 2 h following pridopidine administration (90 mg). Receptor occupancy was analyzed by the Lassen plot. Results S1R occupancy as function of pridopidine dose (or plasma concentration) in HVs could be described by a threeparameter Hill equation with a Hill coefficient larger than one. A high degree of S1R occupancy (87% to 91%) was found throughout the brain at pridopidine doses ranging from 22.5 to 90 mg. S1R occupancy was 43% at 1 mg pridopidine. In contrast, at 90 mg pridopidine, the D2/D3R occupancy was only minimal (~ 3%). Conclusions Our PET findings indicate that at clinically relevant single dose of 90 mg, pridopidine acts as a selective S1R ligand showing near to complete S1R occupancy with negligible occupancy of the D2/D3R. The dose S1R occupancy relationship suggests cooperative binding of pridopidine to the S1R. Our findings provide significant clarification about pridopidine’s mechanism of action and support further use of the 45-mg twice-daily dose to achieve full and selective targeting of the S1R in future clinical trials of neurodegenerative disorders. Clinical Trials.gov Identifier: NCT03019289 January 12, 2017; EUDRA-CT-Nr. 2016-001757-41. Keywords [18F]fluspidine . PET . Pridopidine . Sigma-1receptoroccupancy . Dopamine D2/D3 receptoroccupancy . Huntington disease
Igor D. Grachev and Philipp M. Meyer contributed equally to this work. This article is part of the Topical Collection
Data Loading...
